AR076772A1 - Compuestos 1-(2-alquil-2-3-dihidro-benzofuran-4-il)-pirrolidin-3-ilaminoacilo; producto medicinal preparado a partir del mismo y su uso; composicion farmaceutica que comprende a dicho compuesto; producto medicinal preparado a partir de esta y su uso; procedimiento de tratamiento o prevencion de enfe - Google Patents

Compuestos 1-(2-alquil-2-3-dihidro-benzofuran-4-il)-pirrolidin-3-ilaminoacilo; producto medicinal preparado a partir del mismo y su uso; composicion farmaceutica que comprende a dicho compuesto; producto medicinal preparado a partir de esta y su uso; procedimiento de tratamiento o prevencion de enfe

Info

Publication number
AR076772A1
AR076772A1 ARP100101684A ARP100101684A AR076772A1 AR 076772 A1 AR076772 A1 AR 076772A1 AR P100101684 A ARP100101684 A AR P100101684A AR P100101684 A ARP100101684 A AR P100101684A AR 076772 A1 AR076772 A1 AR 076772A1
Authority
AR
Argentina
Prior art keywords
dihydrobenzofuran
pyrrolidin
methyl
fluoro
product prepared
Prior art date
Application number
ARP100101684A
Other languages
English (en)
Inventor
Josep Lluis Falco
Albert Palomer
Original Assignee
Ferrer Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferrer Int filed Critical Ferrer Int
Publication of AR076772A1 publication Critical patent/AR076772A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Reivindicacion 1: Un derivado 1-(2-aIquiI-2,3-dihidro-benzofuran-4-iI)-pirroIidin-3-iIaminoaciIo, caracterizado porque el compuesto se selecciona del grupo constituido por (i) N-((3S)-1-(7-fluoro-2-metil-2,3-dihidrobenzofuran-4-il)pirrolidin-3-iI)acetamida; (ii) 2,2,2-trifluoro-N-((3S)-1-(7-fluoro-2-metil-2,3-dihidrobenzofuran-4-iI)pirrolidin-3-iI)acetamida; (iii) N-((3S)-1-(7-fluoro-2-metil-2,3-dihidrobenzofuran-4-iI)pirrolidin-3-iI)propionamida; (iv) 2-fluoro-N-((3S)-1-(7-fluoro-2-metil-2,3-dihidrobenzofuran-4-iI)pirrolidin-3-iI)propanamida; (v) N-((3S)-1-(7-fluoro-2-metil-2,3-dihidrobenzofuran-4-iI)pirrolidin-3-iI)butiramida; (vi) N-((3S)-1-(7-fluoro-2-metil-2,3-dihidrobenzofuran-4-iI)pirrolidin-3-iI)isobutiramida; (vii) N-((3S)-1-(7-fluoro-2-metil-2,3-dihidrobenzofuran-4-il)pirrolidin-3-iI)ciclopropanocarboxamida; (viii) N-((3S)-1-(7-fluoro-2-metil-2,3-dihidrobenzofuran-4-iI)pirrolidin-3-iI)pentanamida; (ix) N-((3S)-1-(7-fluoro-2-metil-2,3-dihidrobenzofuran-4-il)pirrolidin-3-iI)-2-metilbutanamida; (x) (3S)-1-(7-fluoro-2-metil-2,3-dihidrobenzofuran-4-iI)pirrolidin-3-ilcarbamato de metilo; (xi) (3S)-1-(7-fluoro-2-metil-2,3-dihidrobenzofuran-4-il)pirrolidin-3-ilcarbamato de etilo; (xii) 1-etil-3-((3S)-1-(7-fluoro-2-metil-2,3-dihidrobenzofuran-4-il)pirroIidin-3-il)urea; (xiii) N-((3S)-1-(2-metil-2,3-dihidrobenzofuran-4-il)pirrolidin-3-il)acetamida; (xiv) 2,2,2-trifluoro-N-((3S)-1-(2-metil-2,3-dihidrobenzofuran-4-il)pirrolidin-3-il)acetamida; (xv) N-((3S)-1-(2-metil-2,3-dihidrobenzofuran-4-il)pirrolidin-3-iI)propionamida; (xvi) N-((3S)-1-(2-metil-2,3-dihidrobenzofuran-4-il)pirrolidin-3-il)isobutiramida; (xvii) N-((3S)-1 -(2-metil-2,3-dihidrobenzofuran-4-il)pirrolidin-3-il)ciclopropanocarboxamida; (xviii) 3-metil-N-((3S)-1-(2-metil-2,3-dihidrobenzofuran-4-il)pirrolidin-3-il)butanamida; (xix) N-((3S)-1-(2-etil-2,3-dihidrobenzofuran-4-il)pirrolidin-3-il)acetamida; (xx) N-((3S)-1-(2-etil-2,3-dihidrobenzofuran-4-iI)pirrolidin-3-il)propionamida; y (xxi) N-((3S)-1-(2-propil-2,3-dihidrobenzofuran-4-iI)pirrolidin-3-il)propionamida; y una sal, solvato, hidrato farmacéuticamente aceptable, o una forma enantiomérica de los mismos.
ARP100101684A 2009-06-15 2010-05-14 Compuestos 1-(2-alquil-2-3-dihidro-benzofuran-4-il)-pirrolidin-3-ilaminoacilo; producto medicinal preparado a partir del mismo y su uso; composicion farmaceutica que comprende a dicho compuesto; producto medicinal preparado a partir de esta y su uso; procedimiento de tratamiento o prevencion de enfe AR076772A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09162731A EP2266975A1 (en) 2009-06-15 2009-06-15 1-(2-alkyl-2,3-dihydro-benzofuran-4-yl)-pyrrolidin-3-ylamine acyl compounds

Publications (1)

Publication Number Publication Date
AR076772A1 true AR076772A1 (es) 2011-07-06

Family

ID=41136948

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101684A AR076772A1 (es) 2009-06-15 2010-05-14 Compuestos 1-(2-alquil-2-3-dihidro-benzofuran-4-il)-pirrolidin-3-ilaminoacilo; producto medicinal preparado a partir del mismo y su uso; composicion farmaceutica que comprende a dicho compuesto; producto medicinal preparado a partir de esta y su uso; procedimiento de tratamiento o prevencion de enfe

Country Status (15)

Country Link
US (1) US20120088809A1 (es)
EP (2) EP2266975A1 (es)
JP (1) JP2012530097A (es)
KR (1) KR20120036840A (es)
CN (1) CN102803253A (es)
AR (1) AR076772A1 (es)
AU (1) AU2010261961A1 (es)
CA (1) CA2762304A1 (es)
CL (1) CL2011003165A1 (es)
MX (1) MX2011013073A (es)
PE (1) PE20120488A1 (es)
RU (1) RU2012101227A (es)
TW (1) TW201102381A (es)
UY (1) UY32654A (es)
WO (1) WO2010145989A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015032005A1 (en) 2013-09-09 2015-03-12 Chu-Sainte-Justine New marker for the classification, diagnosis and treatment of scoliosis
BR112016014006A2 (pt) 2013-12-18 2017-08-08 Monsanto Technology Llc Processos para a diazotização de 2,5-dicloroanilinas
CN116253704A (zh) * 2021-12-10 2023-06-13 中国科学院昆明植物研究所 Paeoveitol D衍生物及其药物组合物和其制备方法与其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2213022T3 (es) * 1999-06-30 2004-08-16 Bristol-Myers Squibb Company Derivados de aminopirrolidina heterociclicos utiles como agentes melatonergicos.
EP2029564A4 (en) * 2006-05-22 2010-01-13 Vanda Pharmaceuticals Inc TREATMENT OF DEPRESSIVE DISORDERS

Also Published As

Publication number Publication date
AU2010261961A1 (en) 2011-12-08
UY32654A (es) 2010-11-30
EP2443108A1 (en) 2012-04-25
EP2266975A1 (en) 2010-12-29
MX2011013073A (es) 2012-02-28
KR20120036840A (ko) 2012-04-18
CN102803253A (zh) 2012-11-28
US20120088809A1 (en) 2012-04-12
JP2012530097A (ja) 2012-11-29
WO2010145989A1 (en) 2010-12-23
CL2011003165A1 (es) 2012-07-06
TW201102381A (en) 2011-01-16
PE20120488A1 (es) 2012-04-27
CA2762304A1 (en) 2010-12-23
RU2012101227A (ru) 2013-07-27

Similar Documents

Publication Publication Date Title
TW200745111A (en) New compounds
BRPI0414581C1 (pt) composto, composição farmacêutica compreendendo o referido composto e uso do referido composto
BRPI0409227B8 (pt) "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)"
WO2004076386A3 (en) Carbamic acid compounds comprising a bicyclic heteroaryl group as hdac inhibitors
CY1113269T1 (el) Παραγωγα ινδαζολυλ αμιδιου για τη θεραπευτικη αγωγη διαταραχων διαμεσολαβουμενων υπο υποδοχεα γλυκοκορτικοειδων
CA2495967A1 (fr) Nouveau procede de synthese et nouvelle forme cristalline de l'agomelatine ainsi que les compositions pharmaceutiques qui la contiennent
PE20091577A1 (es) Inhibidores de cinasa pim y metodos para su uso
MY149183A (en) Heterocyclic aspartyl protease inhibitors
EA201170742A1 (ru) Производные n-{[(1r,4s,6r)-3-(2-пиридинилкарбонил)-3-азабицикло[4.1.0]гепт-4-ил]метил}-2-гетероариламинов и их применения
ATE435855T1 (de) Verbindungen mit agonistischer wirkung am beta2- adrenergen rezeptor und am muscarinischen rezeptor
JP2007523049A5 (es)
DE602004024375D1 (de) Carboxamidderivate
AR060974A1 (es) Compuesto de 4-piridinona, su uso para la preparacion de un medicamento, composicion farmaceutica que lo comprende, proceso para su preparacion y proceso para la preparacion de un compuesto intermediario de utilidad en el anterior
PE20130230A1 (es) Derivados de carboxamidas n-azabiciclicas y su preparacion
NZ620208A (en) Substituted n-[1-cyano-2-(phenyl)ethyl]-2-azabicyclo[2,2,1]heptane-3-carboxamide inhibitors of cathepsin c
ATE440833T1 (de) Antithrombotische diamide
CL2008002295A1 (es) Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
CY1109962T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4,5]δεκαν-2-ονης για τη θεραπεια παχυσαρκιας
HRP20100577T1 (hr) Uporaba agomelatina za dobivanje lijeka s ciljem liječenja općeg poremećaja anksioznosti
WO2010129057A3 (en) Tetracycline compounds
TW200800984A (en) New compounds
AR076772A1 (es) Compuestos 1-(2-alquil-2-3-dihidro-benzofuran-4-il)-pirrolidin-3-ilaminoacilo; producto medicinal preparado a partir del mismo y su uso; composicion farmaceutica que comprende a dicho compuesto; producto medicinal preparado a partir de esta y su uso; procedimiento de tratamiento o prevencion de enfe
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
NO20055601L (no) Farmasoytisk preparat i form av en hydrogel for transdermal administrasjon av aktive virkestoffer
AR062112A1 (es) Derivados ciclicos como moduladores de la actividad del receptor de quimiocina

Legal Events

Date Code Title Description
FB Suspension of granting procedure